Placebo ophthalmic solution and 3% DE-089 ophthalmic solution
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dry Eye Disease
Conditions
Dry Eye Disease
Trial Timeline
Sep 8, 2017 → Feb 1, 2018
NCT ID
NCT03216096About Placebo ophthalmic solution and 3% DE-089 ophthalmic solution
Placebo ophthalmic solution and 3% DE-089 ophthalmic solution is a phase 1 stage product being developed by Santen Pharmaceutical for Dry Eye Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03216096. Target conditions include Dry Eye Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03216096 | Phase 1 | Completed |
Competing Products
20 competing products in Dry Eye Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| UB-312 + Placebo | Vaxxinity | Phase 1 | 25 |
| [18F]NAV4694 | Navidea Biopharmaceuticals | Phase 2 | 44 |
| Bromocriptine Mesilate + Placebos | Towa Pharmaceutical | Phase 1/2 | 40 |
| exidavnemab + Placebo Comparator | BioArctic AB | Phase 2 | 49 |
| Abiprubart + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| atomoxetine + Matching Placebo | Eli Lilly | Phase 2 | 52 |
| Rosuvastatin 40mg + Placebo | HeartFlow | Pre-clinical | 18 |
| Evolocumab | HeartFlow | Approved | 80 |
| High intensity lipid lowering | HeartFlow | Pre-clinical | 18 |
| Apixaban 5 MG + Apixaban 2.5 MG + Warfarin | Artivion | Phase 3 | 72 |
| Lanifibranor | Inventiva | Phase 2 | 47 |
| LY450139 + Placebo | Eli Lilly | Phase 3 | 77 |
| Dulaglutide + Placebo | Eli Lilly | Phase 3 | 77 |
| raloxifene + placebo | Eli Lilly | Phase 3 | 77 |
| VTX958 + VTX958 + VTX958 Placebo | Ventyx Biosciences | Phase 2 | 47 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| LY450139 dihydrate + placebo | Eli Lilly | Phase 2 | 52 |
| Zagotenemab + Placebo | Eli Lilly | Phase 2 | 52 |
| Donanemab + Placebo + LY3202626 | Eli Lilly | Phase 2 | 52 |
| Donanemab + Placebo | Eli Lilly | Phase 3 | 77 |
Other Products from Santen Pharmaceutical
Eybelis ophthalmic solution 0.002%Approved
85
Aflibercept Injection [Eylea]Approved
85
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Phase 3
77
DE-117B Eye Drops + LatanoprostPhase 3
77
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solutionPhase 3
77